#161783

OV-3133(R2) cell line

Cat. #161783

OV-3133(R2) cell line

Cat. #: 161783

Organism: Human

Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: OV-3133(R2) cell line
  • Alternate name: OV-3133(R2)
  • Cancer: Gynaecologic cancer
  • Research fields: Cancer
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
  • Donor: Grade 3 – Stage IIIC; Mutations: TP53 Exon 6; Carboplatin/Taxol/Doxorubicin & Carboplatin/Gemcitabine/Doxorubicin
  • Morphology: No expression of the tumor suppressor p53 detected. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: aggregate
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse (R). Primary treatment included paclitaxel and carboplatin and later treatment included doxorubicin, carboplatin, gemcitabine, and etoposide.
  • Production details: Established from the cellular fraction of ascites collected by centrifugation. The cell lines were then maintained for 40 days in OSE with medium replaced weekly.
  • Additional notes: Patient 3133 received treatment of paclitaxel and carboplatin 1-3 months after sugery and confirmation of ovarian cancer diagnosis. A second sugery 6 months after the first detectede infiltration of the tumor in part of the abdomen. Patient was treated with dxorubicin and later carboplatin and gemcitabine after no significant changes of CA-125 levels were seen. Later imaging presented an increase in tumor mass whereby she was given etoposide orally for eight days.

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin

References

  • Tomas et al. 2023. J Ovarian Res. 11
  • 16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11
  • 12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11
  • 12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4
  • 12:856424. PMID: 35600398